A big progress in nanomedicine was made during the last decade. Nanomedicines based on inorganic materials, lipids and natural or synthetic polymers were prepared and reached approval by health care authorities. Nanoparticles (NPs) can have inherent therapeutic effects (e.g. induction of oxidative stress or DNA damage), can be used as drug carriers, and can further be used as imaging agents or theranostics. Although the principles of nanomedicine are applicable to a broad range of diseases, treatment of cancer remains the most advanced therapeutic field (summarized in Wicki et al., 2015).
In our group, we use a broad range of nanomaterials for passive and active drug targeting and for imaging and test these systems in various in vitro and in vivo settings.
Modern drug delivery requires a versatile approach when designing and manufacturing dosage forms. Research in the field of classical pharmaceutical technology is constantly challenged by new targets, new substances, various delivery routes, and manufacturing requirements. Modern pharmaceutical technology combines the use of novel techniques and instruments with biological as well as health-related discoveries. Research projects in the field of drug delivery are combining material science to identify new excipients with modern approaches in formulation design, such as computer-based simulations, and clinical R&D.
Our vision is to propose robust strategies to move towards personalized medicine, age appropriate and safe formulations, and increase in patient’s compliance.